Innate Pharma Sa (IPHA)

Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier.

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript May 13, 2026Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.34627, expectations were $-0.34918.

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2025 Earnings Call Transcript November 13, 2025Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.24551, expectations were $-0.32845.

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call Transcript September 17, 2025Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.2963, expectations were $-0.32845.

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Call Transcript May 13, 2025 Operator: Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today.

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript March 27, 2025Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 EPS, expectations were $-0.26681.

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Hello and thank you for standing by. My name is Regina and will be your conference operator today.

Innate Pharma S.A.

Innate Pharma S.A.